Form 8-K IONIS PHARMACEUTICALS For: Feb 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
February 20, 2025 5:50 AM ESTRaymond James analyst Gary Nachman lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $61.00) while maintaining a Strong Buy rating.
The analyst comments "Key Updates. 1) Wainua in ATTR-PN. AZN booked $42M in 4Q (+83% q/q; FY $86M), with ~$10M royalties to IONS (FY $20M). U.S. launch is progressing well with new-to-brand share ~40%; seeing good... More
